HighMark Wealth Management LLC Increases Holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)

HighMark Wealth Management LLC grew its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 41.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 235,785 shares of the company's stock after buying an additional 69,650 shares during the quarter. Centessa Pharmaceuticals makes up about 2.0% of HighMark Wealth Management LLC's investment portfolio, making the stock its 9th largest holding. HighMark Wealth Management LLC owned approximately 0.18% of Centessa Pharmaceuticals worth $3,391,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in CNTA. Janus Henderson Group PLC lifted its holdings in shares of Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock valued at $82,218,000 after buying an additional 3,614,623 shares during the last quarter. Foresite Capital Management VI LLC acquired a new stake in Centessa Pharmaceuticals in the 4th quarter worth approximately $20,994,000. Adage Capital Partners GP L.L.C. lifted its holdings in Centessa Pharmaceuticals by 22.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock worth $85,744,000 after purchasing an additional 924,027 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Centessa Pharmaceuticals by 26.2% in the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock worth $57,396,000 after purchasing an additional 710,936 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Centessa Pharmaceuticals by 14.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock worth $89,854,000 after purchasing an additional 685,371 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CNTA has been the subject of several analyst reports. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price for the company. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price for the company. Chardan Capital initiated coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a "buy" rating and a $30.00 target price for the company. Guggenheim restated a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Finally, Wall Street Zen upgraded Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $27.89.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock traded up $0.01 during trading hours on Monday, reaching $13.14. 1,137,853 shares of the company's stock were exchanged, compared to its average volume of 736,424. Centessa Pharmaceuticals PLC Sponsored ADR has a fifty-two week low of $8.46 and a fifty-two week high of $19.09. The stock has a market capitalization of $1.75 billion, a P/E ratio of -7.26 and a beta of 1.48. The business has a fifty day moving average price of $12.85 and a 200-day moving average price of $14.66. The company has a quick ratio of 14.37, a current ratio of 14.37 and a debt-to-equity ratio of 0.28.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.15. Analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, General Counsel Iqbal J. Hussain sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $14.02, for a total transaction of $168,240.00. Following the sale, the general counsel directly owned 105,386 shares in the company, valued at approximately $1,477,511.72. The trade was a 10.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Arjun Goyal acquired 417,646 shares of the stock in a transaction dated Friday, May 16th. The shares were purchased at an average price of $12.73 per share, for a total transaction of $5,316,633.58. Following the completion of the transaction, the director owned 462,585 shares of the company's stock, valued at $5,888,707.05. This trade represents a 929.36% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 189,398 shares of company stock valued at $2,462,692 in the last quarter. 7.09% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.